CN104884627A - 具有小型启动子盒的逆转录病毒载体 - Google Patents

具有小型启动子盒的逆转录病毒载体 Download PDF

Info

Publication number
CN104884627A
CN104884627A CN201380067486.4A CN201380067486A CN104884627A CN 104884627 A CN104884627 A CN 104884627A CN 201380067486 A CN201380067486 A CN 201380067486A CN 104884627 A CN104884627 A CN 104884627A
Authority
CN
China
Prior art keywords
retrovirus
cell
promotor
sequence
pac3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380067486.4A
Other languages
English (en)
Chinese (zh)
Inventor
海瑞·E·格鲁伯
道格拉斯·J·乔利
艾米·H·林
克里斯多弗·R·洛格
笠原典之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suoyuan Biomedical Usa Co ltd
Original Assignee
Tocagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tocagen Inc filed Critical Tocagen Inc
Publication of CN104884627A publication Critical patent/CN104884627A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201380067486.4A 2012-10-25 2013-10-24 具有小型启动子盒的逆转录病毒载体 Pending CN104884627A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718610P 2012-10-25 2012-10-25
US61/718,610 2012-10-25
PCT/US2013/066709 WO2014066700A1 (en) 2012-10-25 2013-10-24 Retroviral vector with mini-promoter cassette

Publications (1)

Publication Number Publication Date
CN104884627A true CN104884627A (zh) 2015-09-02

Family

ID=50545284

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380067486.4A Pending CN104884627A (zh) 2012-10-25 2013-10-24 具有小型启动子盒的逆转录病毒载体

Country Status (6)

Country Link
US (1) US11065311B2 (enExample)
EP (2) EP2909324B1 (enExample)
JP (3) JP6419706B2 (enExample)
CN (1) CN104884627A (enExample)
ES (1) ES2786051T3 (enExample)
WO (1) WO2014066700A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138201A (zh) * 2015-09-04 2018-06-08 托卡根公司 包含2a肽的重组载体
CN108291208A (zh) * 2015-11-24 2018-07-17 葛兰素史密斯克莱知识产权发展有限公司 用于产生逆转录病毒的稳定细胞系
CN108474003A (zh) * 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
CN116334010A (zh) * 2023-05-30 2023-06-27 中义(北京)健康研究院 一种重组单纯疱疹病毒及其制备方法和应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11230719B2 (en) * 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
CN110225977B (zh) 2016-11-29 2023-05-05 阿迪雷尔有限公司 基因治疗载体系统和药物前体基因
KR20240024326A (ko) 2017-05-19 2024-02-23 엔코디드 테라퓨틱스, 인크. 고활성 조절 요소
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CN111727259B (zh) 2017-12-01 2024-04-19 编码治疗公司 工程化的dna结合蛋白
GB201720948D0 (en) * 2017-12-15 2018-01-31 Autolus Ltd Plasmid system
WO2020102437A1 (en) * 2018-11-13 2020-05-22 Tocagen Inc. Recombinant vectors comprising genes for binding domains and secretable peptides
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
EP4096670A4 (en) * 2020-01-30 2024-02-28 Purdue Research Foundation LIGAND-MEDIATED DELIVERY OF THERAPEUTIC PROTEINS AND THEIR USES
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
KR20250006965A (ko) 2022-04-29 2025-01-13 퓨리노미아 바이오테크, 아이엔씨. 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004266A1 (en) * 1999-07-08 2001-01-18 The Regents Of The Universty Of California A lung cancer associated retrovirus, gene delivery vector and methods of use thereof
US20050002903A1 (en) * 1998-10-01 2005-01-06 Noriyuki Kasahara Gene delivery system and methods of use
WO2006127980A2 (en) * 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
US20070281898A1 (en) * 2001-09-21 2007-12-06 Oxford Biomedica (Uk) Limited Vector
WO2011126864A2 (en) * 2010-03-29 2011-10-13 Tocagen Inc. Cancer treatment with recombinant vector
WO2012021794A1 (en) * 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Chimeric promoters and methods of use
US20120052554A1 (en) * 1998-10-01 2012-03-01 University Of Southern California Gene delivery system and method of use

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5997859A (en) 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
DE68921034D1 (de) 1988-09-27 1995-03-23 Dana Farber Cancer Inst Inc Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält.
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
WO1993003143A1 (en) 1991-08-07 1993-02-18 Anderson W French Retroviral vectors containing internal ribosome entry sites
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
AU688292B2 (en) 1992-11-09 1998-03-12 United States Government as represented by the Department of Health and Human Services, The Targetable vector particles
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
JPH08511156A (ja) 1993-04-06 1996-11-26 アメリカ合衆国 テナガザル白血球ウイルスベースのレトロウイルスベクター
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
AU708972B2 (en) 1994-11-07 1999-08-19 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US20030157070A1 (en) 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6117681A (en) 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
JPH11507205A (ja) 1995-04-27 1999-06-29 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子受容体
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
GB9604354D0 (en) 1996-02-29 1996-05-01 Isis Innovation Targeting adapters
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1998006842A1 (en) 1996-08-16 1998-02-19 Schering Corporation Mammalian cell surface antigens; related reagents
ES2316153T3 (es) 1996-08-16 2009-04-01 Human Genome Sciences, Inc. Endoquina alfa humana.
US6025192A (en) 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
BR9612752A (pt) 1996-10-25 2000-01-18 Human Genome Sciences Inc Neutrocina
ATE321855T1 (de) 1997-01-14 2006-04-15 Human Genome Sciences Inc Tumor-nekrose-faktor rezeptor 5
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
WO1998054202A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
WO1998056892A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
WO1999020742A2 (en) 1997-10-20 1999-04-29 Universita' Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
FR2773561A1 (fr) 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
US6451304B1 (en) 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
AU758155B2 (en) 1998-04-29 2003-03-13 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
FR2778670B1 (fr) 1998-05-18 2002-12-13 Rhone Poulenc Rorer Sa Methodes et compositions pour la production de particules virales
GB9810752D0 (en) 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
US6448390B1 (en) 1998-05-20 2002-09-10 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
US6576463B1 (en) 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
CA2371946A1 (en) 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
EP1059356B1 (en) 1999-06-09 2005-11-02 Universite Pierre Et Marie Curie Paris Vi Replicating retroviral constructs, preparation and uses for gene delivery
EP1059357A1 (en) 1999-06-09 2000-12-13 Universite Pierre Et Marie Curie Paris Vi Replicating or semi-replicating retroviral constructs, preparation and uses for gene delivery
WO2001040488A1 (en) 1999-11-30 2001-06-07 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
US6322696B1 (en) 2000-02-25 2001-11-27 Gp Companies, Inc. Inlet filter for high pressure sprayer
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
AU2001292711A1 (en) 2000-09-18 2002-03-26 Genetic Therapy, Inc. Stress resistant retroviruses
GB0024550D0 (enExample) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US20030003565A1 (en) 2000-11-27 2003-01-02 Dubensky Thomas W. Functional lentiviral vector from an MLV-based backbone
US7226779B2 (en) 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
JP2004532039A (ja) 2001-03-26 2004-10-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ヘルパー依存性アデノウイルスベクター系およびその系の使用方法
US7211247B2 (en) 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
JP2002335965A (ja) 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
JP2005510491A (ja) 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療
FR2832424B1 (fr) 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations
US20030121068A1 (en) 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
AU2003206815A2 (en) 2002-02-01 2003-09-02 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with PODs
CA2524892A1 (en) 2002-05-17 2003-11-27 Retrovec Aps A purified polypeptide, isolated nucleic acids encoding said polypeptide, vectors and use thereof
MXPA05000647A (es) 2002-07-17 2005-03-31 Squibb Bristol Myers Co Mamiferos no humanos transgenicos que expresan un acido nucleico reportero bajo regulacion de los elementos de respuesta de androgenos.
EP1534847B1 (en) 2002-09-03 2015-10-28 Oxford Biomedica (UK) Limited Retroviral vector and stable packaging cell lines
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005118802A2 (en) 2004-06-03 2005-12-15 The Regents Of The University Of California Targeting pseudotyped retroviral vectors
US20070003522A1 (en) 2004-07-08 2007-01-04 Albritton Lorraine M Methods and compositions for improved retroviral gene and drug delivery
BRPI0515735A2 (pt) 2004-11-04 2011-10-11 Pfizer Prod Inc tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos
AU2005309485A1 (en) 2004-11-24 2006-06-01 Nanovector Limited Viral vectors
US20060147429A1 (en) 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
US20070048285A1 (en) 2005-08-24 2007-03-01 Christopher Baum Self-inactivating retroviral vector
WO2007036233A2 (en) 2005-09-30 2007-04-05 Zgene A/S Dekkera/brettanomyces cytosine deaminases and their use
EP2386564B1 (en) 2005-10-01 2014-07-16 Charles Stout Regulatable fusion promoters
WO2007044483A2 (en) 2005-10-07 2007-04-19 President And Fellows Of Harvard College Attenuated vaccines for non-segmented negative sense rna viruses
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
EP2487260B1 (en) 2006-01-05 2015-07-08 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007095201A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California Pseudotyped retroviral vectors and methods of use thereof
WO2007107156A2 (en) 2006-03-17 2007-09-27 Aarhus Universitet Chimeric viral envelopes
SI2012816T1 (sl) 2006-05-02 2012-09-28 Sigma Tau Ind Farmaceuti Uporaba timozina 1, samega ali v kombinaciji s PTX3 ali ganciklovirjem, za zdravljenje citomegalovirusne infekcije
SG173337A1 (en) 2006-07-21 2011-08-29 California Inst Of Techn Targeted gene delivery for dendritic cell vaccination
WO2008151633A2 (en) 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
WO2010036986A2 (en) 2008-09-26 2010-04-01 Tocagen Inc. Recombinant vectors
SG176890A1 (en) 2009-06-17 2012-01-30 Tocagen Inc Producer cells for replication competent retroviral vectors
WO2012058673A2 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
KR101888391B1 (ko) 2014-09-01 2018-08-14 삼성전자 주식회사 음성 신호 관리 방법 및 이를 제공하는 전자 장치

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002903A1 (en) * 1998-10-01 2005-01-06 Noriyuki Kasahara Gene delivery system and methods of use
US20120052554A1 (en) * 1998-10-01 2012-03-01 University Of Southern California Gene delivery system and method of use
WO2001004266A1 (en) * 1999-07-08 2001-01-18 The Regents Of The Universty Of California A lung cancer associated retrovirus, gene delivery vector and methods of use thereof
US20070281898A1 (en) * 2001-09-21 2007-12-06 Oxford Biomedica (Uk) Limited Vector
WO2006127980A2 (en) * 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
WO2011126864A2 (en) * 2010-03-29 2011-10-13 Tocagen Inc. Cancer treatment with recombinant vector
WO2012021794A1 (en) * 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Chimeric promoters and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JING CHAO ZHAO-EMONET 等: "T Cell-specific expression from Mo-MLV retroviral vectors containing a CD4 mini-promoter/enhancer", 《JOURNAL OF GENE MEDICINE》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138201A (zh) * 2015-09-04 2018-06-08 托卡根公司 包含2a肽的重组载体
CN108474003A (zh) * 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
CN108291208A (zh) * 2015-11-24 2018-07-17 葛兰素史密斯克莱知识产权发展有限公司 用于产生逆转录病毒的稳定细胞系
CN116334010A (zh) * 2023-05-30 2023-06-27 中义(北京)健康研究院 一种重组单纯疱疹病毒及其制备方法和应用
CN116334010B (zh) * 2023-05-30 2023-08-29 中义(北京)健康研究院 一种重组单纯疱疹病毒及其制备方法和应用
WO2024244306A1 (zh) * 2023-05-30 2024-12-05 中义（苏州）生物制药有限公司 一种重组单纯疱疹病毒及其制备方法和应用

Also Published As

Publication number Publication date
EP3623478A1 (en) 2020-03-18
ES2786051T3 (es) 2020-10-08
US20150273029A1 (en) 2015-10-01
US11065311B2 (en) 2021-07-20
JP2015533510A (ja) 2015-11-26
WO2014066700A1 (en) 2014-05-01
JP6419706B2 (ja) 2018-11-07
EP2909324A1 (en) 2015-08-26
JP2021006031A (ja) 2021-01-21
EP2909324B1 (en) 2020-02-26
JP2018183155A (ja) 2018-11-22
EP2909324A4 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
CN104884627A (zh) 具有小型启动子盒的逆转录病毒载体
US20220195460A1 (en) Retroviral vector having immune-stimulating activity
US10407666B2 (en) Recombinant vectors
JP6523224B2 (ja) 組換えベクター
EP3159415B1 (en) Producer cells for replication competent retroviral vectors
JP2018526007A (ja) ２ａペプチドを含む組換えベクター
CN105579581A (zh) 具有优化的a凸出物的重组载体
US20160222412A1 (en) Recombinant vector with stabilizing a-loop

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210525

Address after: California, USA

Applicant after: Suoyuan biomedical (USA) Co.,Ltd.

Address before: California, USA

Applicant before: Tocagen Inc.

TA01 Transfer of patent application right